Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BEX2
has been suggested to promote the
tumor growth
in breast cancer and glioblastoma, while inhibit the proliferation of glioma cells. Thus, the role of
BEX2
in tumor was still in debate. Additionally, the biological functions of
BEX2
in colorectal cancer (CRC) have not yet been clarified. Here, we reported that
BEX2
was overexpressed in advanced CRC from both the GSE14333 database and fresh CRC tissue specimens, and positively correlated with clinical staging. Knockdown of
BEX2
significantly decreased the
in vitro
proliferation of SW620 colorectal cancer cells, suppressed subcutaneous xenograft growth and enhanced the survival of mice with cecal tumors. These effects were mainly mediated by the JNK/c-Jun pathway. Knockdown of
BEX2
inhibited JNK/c-Jun phosphorylation, while
BEX2
overexpression activated JNK/c-Jun phosphorylation. Moreover, the administration of the JNK-specific inhibitor SP600125 to SW620 with
BEX2
overexpression abolished the effect of
BEX2
on SW620 cell proliferation. This study reveals that
BEX2
promotes colorectal cancer cell proliferation via the JNK/c-Jun pathway, suggesting
BEX2
as a potential candidate target for the treatment of CRC.
...
PMID:BEX2 promotes tumor proliferation in colorectal cancer. 2836 93
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Accumulating studies have revealed that microRNAs (miRNAs) play a critical role in the development and progression of HCC. Through microarray-based gene expression profiling of HCC, miR-370, and
BEX2
were identified in HCC. Hence, this study aimed to evaluate their abilities on the cellular processes in HCC. It was determined that
BEX2
was highly expressed and miR-370 was poorly expressed in HCC cell lines and tissues. Then, the cell line presenting with the highest
BEX2
expression and the lowest miR-370 expression was selected for subsequent gain- and loss-of-function experimentation. The antitumor effect of miR-370 on HCC cell proliferation, invasion, migration, and apoptosis, as well as the MAPK/JNK signaling pathway was examined. Meanwhile, the interaction among miR-370,
BEX2
, and MAPK/JNK signaling pathway was identified.
BEX2
is verified to be a target of miR-370. Moreover, miR-370 exerted antitumor effect on HCC development through suppression of the MAPK/JNK signaling pathway by targeting
BEX2
. Later, it was further verified by in vivo experiment that overexpression of miR-370 inhibited
tumor growth
. Above results provide evidence that miR-370 could downregulate
BEX2
gene and inhibit activation of MAPK/JNK signaling pathway, thus inhibiting the development of HCC. It provides a worth-trying novel therapeutic target for HCC treatment.
...
PMID:MicroRNA-370 functions as a tumor suppressor in hepatocellular carcinoma via inhibition of the MAPK/JNK signaling pathway by targeting BEX2. 3153 Sep 37